Evaluation of the Effectiveness of Workshops on the Availability and Rational Use of Opioids in Latin America

Journal of Palliative Medicine

Volumn 19, Issue 9, 2016, Pages 964-971

  De Lima, Liliana ^a   Pastrana, Tania ^b  

^a International Association for Hospice and Palliative Care (IAHPC)   (United States)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE DERIVATIVE; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ARTICLE; BOLIVIA; CHILE; COLOMBIA; CONTENT ANALYSIS; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; COSTA RICA; CROSS-SECTIONAL STUDY; DRUG FORMULATION; DRUG USE; DRUG UTILIZATION; ECUADOR; EL SALVADOR; EVALUATION STUDY; GUATEMALA; HEALTH PROGRAM; HONDURAS; HUMAN; HUMAN DEVELOPMENT INDEX; METHODOLOGY; MEXICO; NICARAGUA; NONPARAMETRIC TEST; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PANAMA; PERU; PROGRAM EFFECTIVENESS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANK SUM TEST; SOUTH AND CENTRAL AMERICA; STATISTICAL MODEL; VENEZUELA; WORKSHOP;

ANALGESICS, OPIOID; CROSS-SECTIONAL STUDIES; HUMANS; LATIN AMERICA;

EID: 84984673717     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2016.0091     Document Type: Article

References (34)

1. Pastrana T, De Lima L, Wenk R, et al.: Atlas de Cuidados Paliativos de Latinoamérica ALCP. 1a edición ed. Houston: IAHPC Press, 2012.
2. World Bank: Country and Lending Groups. http://data. worldbank.org/about/country-and-lending-groups#LAC. 2015. (Last accessed February 15, 2016).
3. Alwan A, Maclean DR, Riley LM, et al.: Monitoring and surveillance of chronic non-communicable diseases: Progress and capacity in high-burden countries. Lancet 2010; 376:1861-1868.
4. Sheinfeld Gorin S, Krebs P, Badr H, et al.: Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. J Clin Oncol 2012;30:539-547.
5. World Health Organization (WHO): Palliative Care. Fact sheet No. 402, July 2015.. www.who.int/mediacentre/factsheets/fs402/en. 2015. (Last accessed February 13, 2016).
6. Colson J, Koyyalagunta D, Falco FJ, Manchikanti L: A systematic review of observational studies on the effectiveness of opioid therapy for cancer pain. Pain physician 2011;14:E85-E102.
7. World Health Organization (WHO): Access to Controlled Medicines Programme: Improving Access to Medications Controlled Under International Drug Conventions. Geneva: WHO Press, 2007. www.who.int/medicines/areas/quality- safety/Framework-ACMP-withcover.pdf (Last accessed February 15, 2016).
8. World Health Organization (WHO): 19th Model List of Essential Medicines. Geneva: WHO, 2015. www.who.int/selection-medicines/committees/expert/20/EML-2015- FINAL-amended-AUG2015.pdf?ua=1 (Last accessed February 15, 2016).
9. World Health Organization (WHO): WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy-2000-2003. Geneva: WHO, 2000. http://apps.who. int/medicinedocs/pdf/whozip16e/whozip16e.pdf (Last accessed February 15, 2016).
10. International Narcotics Control Board (INCB): Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purpose. New York: UN, 2016.
11. Human Rights Watch (HRW): ''Please do not make us suffer any more.''. Access to Pain Treatment as a Human Right. New York: Human Rights Watch, 2009. www.hrw. org/reports/2009/03/02/please-do-not-make-us-suffer-anymore (Last accessed February 15, 2016).
12. Cherny NI, Cleary J, Scholten W, et al.: The Global Opioid Policy Initiative (GOPI) project to evaluate the availability and accessibility of opioids for the management of cancer pain in Africa, Asia, Latin America and the Caribbean, and the Middle East: Introduction and methodology. Ann Oncol 2013;24(suppl 11):xi7-xi13.
13. International Narcotics Control Board (INCB): Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes. New York: United Nations, 2011, E/INCB/2010/1/Supp.1.
14. Cherny NI, Baselga J, de Conno F, Radbruch L: Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: A report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol 2010;21:615-626.
15. Redmond K: Organizational barriers in opioid use. Support Care Cancer 1997;5:451-456.
16. Davis MP, Walsh D: Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp Palliat Care 2004;21:137-142.
17. De Lima L, Pastrana T, Radbruch L, Wenk R: Crosssectional pilot study to monitor the availability, dispensed prices, and affordability of opioids around the globe. J Pain Symptom Manage 2014;48:649-659 e1.
18. Bosnjak S, Maurer MA, Ryan KM, et al. Improving the availability and accessibility of opioids for the treatment of pain: The International Pain Policy Fellowship. Support Care Cancer 2011;19:1239-1247.
19. Joranson DE: Improving availability of opioid pain medications: Testing the principle of balance in Latin America. J Palliat Med 2004;7:105-114.
20. World Health Organization (WHO): Ensuring Balance in National Policies on Controlled Substances: Guidance for Availability and Accessibility of Controlled Medicines. Geneva: WHO, 2011. www.unodc.org/docs/treatment/Pain/WHO-encuring-balance-controlled-substances.pdf (Last accessed February 15, 2016).
21. Linge-Dahl L, Vranken M, Juenger S, et al.: Identification of challenges to the availability and accessibility of opioids in twelve European countries: Conclusions from two ATOME six-country workshops. J Palliat Med 2015;18: 1033-1039.
22. Powell RA, Kaye RM, Ddungu H, Mwangi-Powell F: Advancing drug availability-experiences from Africa. J Pain Symptom Manage 2010;40:9-12.
23. De Lima L, Doyle D: The International Association for Hospice and Palliative Care list of essential medicines for palliative care. J Pain Palliat Care Pharmacother 2007;21: 29-36.
24. Pain & Policy Studies Group (PPSG): Opioid consumption data-AMRO/PAHO. www.painpolicy.wisc.edu/country profiles/amro. 2013. (Last accessed February 15, 2016).
25. United Nations Development Programme (UNDP): Human Development Report. International Human Development Indicators. http://hdr.undp.org/en/countries. 2016. (Last accessed February 15, 2016).
26. United Nations Development Programme (UNDP): Human Development Report. Human Development Index. http://hdr.undp.org/en/content/human-development-index-hdi. 2016. (Last accessed March 18, 2016).
27. Bruera E, Palmer JL, Bosnjak S, et al.: Methadone versus morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study. J Clin Oncol 2004;22:185-192.
28. Vranken MJ, Lisman JA, Mantel-Teeuwisse AK, et al.: Barriers to access to opioid medicines: A review of national legislation and regulations of 11 central and eastern European countries. Lancet Oncol 2016;17:e13-e22.
29. World Bank: Ease of doing business index. http://data. worldbank.org/indicator/IC.BUS.EASE.XQ. 2016. 2016. (Last accessed March 18, 2016).
30. Lohman D, Burke-Shyne N: The Impact of International Drug Policy on Access to Controlled Medicines. New York: Open Society Foundations, 2015.
31. Human Rights Watch (HRW): National Drug Control Strategies and Access to Controlled Medicines. www.hrw. org/supporting-resources/286317/national-drug-controlstrategies-and-access-controlled-medicines. 2015. (Last accessed February 15, 2016).
32. United Nations (UN): Single Convention on Narcotic Drugs. New York: UN, 1961.
33. United Nations (UN): Convention on Psychotropic Substances. New York: UN, 1971.
34. International Narcotics Control Board (INCB), World Health Organization (WHO): Guide on Estimating Requirements for Substances under International Control. New York: UN, 2012.